| Literature DB >> 27618740 |
Iosif Pediaditakis1, Paschalis Efstathopoulos1, Kyriakos C Prousis2, Maria Zervou2, Juan Carlos Arévalo3, Vasileia I Alexaki4, Vassiliki Nikoletopoulou5, Efthymia Karagianni6, Constantinos Potamitis2, Nektarios Tavernarakis5, Triantafyllos Chavakis4, Andrew N Margioris6, Maria Venihaki6, Theodora Calogeropoulou2, Ioannis Charalampopoulos7, Achille Gravanis8.
Abstract
Nerve growth factor (NGF) holds a pivotal role in brain development and maintenance, been also involved in the pathophysiology of neurodegenerative diseases. Here, we provide evidence that a novel C17-spiroepoxy steroid derivative, BNN27, specifically interacts with and activates the TrkA receptor of NGF, inducing phosphorylation of TrkA tyrosine residues and down-stream neuronal survival-related kinase signaling. Additionally, BNN27 potentiates the efficacy of low levels of NGF, by facilitating its binding to the TrkA receptors and differentially inducing fast return of internalized TrkA receptors into neuronal cell membranes. Furthermore, BNN27 synergizes with NGF in promoting axonal outgrowth, effectively rescues from apoptosis NGF-dependent and TrkA positive sympathetic and sensory neurons, in vitro, ex vivo and in vivo in NGF null mice. Interestingly, BNN27 does not possess the hyperalgesic properties of NGF. BNN27 represents a lead molecule for the development of neuroprotective TrkA receptor agonists, with potential therapeutic applications in neurodegenerative diseases and in brain trauma.Entities:
Keywords: Molecular modeling; Nerve growth factor (NGF); Neurodegeneration; Neuronal apoptosis; Neurotrophin receptors signaling; Neurotrophins; STD NMR; Steroid; TrkA
Mesh:
Substances:
Year: 2016 PMID: 27618740 DOI: 10.1016/j.neuropharm.2016.09.007
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250